Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2013
11/28/2013US20130316986 Anti-Thrombotic Compounds
11/28/2013US20130316981 Tertiary amines, medicaments containing said amines, use thereof and processes for the preparation thereof
11/28/2013US20130316978 Boronic acid derivatives and therapeutic uses thereof
11/28/2013US20130316961 Treatment of mecp-2 associated disorders
11/28/2013US20130316955 Aminostatin derivatives for the treatment of arthrosis
11/28/2013US20130316954 Methods of Treating Depression and Other Related Diseases
11/28/2013US20130316941 Glucagon analogues
11/28/2013US20130316026 Xylitol-based anti-mucosal compositions and related methods and compositions
11/28/2013US20130316017 Oral Composition for the Treatment of Acne
11/28/2013US20130315994 Modified-release dosage forms of 5-ht2c agonists useful for weight management
11/28/2013US20130315984 Anti-trypanosomal peptides and uses thereof
11/28/2013US20130315983 Methods and compositions for the treatment of cancer
11/28/2013US20130315975 Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor
11/28/2013US20130315965 Harmine derivatives for promoting bone growth
11/28/2013US20130315945 Yeast-based vaccines as immunotherapy
11/28/2013US20130315927 Pcsk9 antagonists
11/28/2013US20130315903 Arylsulfonamide derivatives for the prevention or treatment of specific ophthalmologic disorders
11/28/2013US20130315897 Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor
11/28/2013US20130315895 COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
11/28/2013US20130315868 D-amino acid compounds for liver disease
11/28/2013US20130315867 3',5'-cyclic phosphate prodrugs for hcv infection
11/28/2013US20130315866 3',5'-cyclic phosphoramidate prodrugs for hcv infection
11/28/2013US20130315865 Triazine compounds as pi3 kinase and mtor inhibitors
11/28/2013US20130315864 Macrocyclic nucleoside phosphoramidate derivatives
11/28/2013US20130315861 Inhibitors of flaviviridae viruses
11/28/2013US20130315859 Anti-inflammatory compositions
11/28/2013US20130315820 Use of an antibody directed against a membrane protein
11/27/2013EP2666481A2 Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient
11/27/2013EP2666475A1 Therapeutic agent for alopecia
11/27/2013EP2666358A1 Treating Psychological Conditions Using Muscarinic Receptor M1 Antagonists
11/27/2013EP2665738A1 Compounds for use in the treatment of bacterial infection
11/27/2013EP2665472A1 Compounds for treatment of heart failure
11/27/2013CN103415292A Androgen composition for treating an opthalmic condition
11/27/2013CN103415291A Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone by using a dosing algorithm to provide analgesia
11/27/2013CN103415283A Liposome formulation comprising an anti-tumour active substance, method for its preparation and pharmaceutical compositions comprising it
11/27/2013CN103405771A Pharmaceutical composition and applications thereof
11/27/2013CN103405770A Application of CDK2 antagonist as differentiation therapy drug sensitizer
11/26/2013US8592420 Method of treating an anxiety disorder
11/26/2013US8592397 Compositions and methods for combination antiviral therapy
11/26/2013US8592392 Multiple antioxidant micronutrients
11/26/2013US8592371 Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
11/26/2013US8592152 Gene detection assay for improving the likelihood of an effective response to an EGFR antagonist cancer therapy
11/26/2013US8591897 Anti-ERBB2 antibody adjuvant therapy
11/26/2013US8591890 Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
11/26/2013US8591874 Inhibition of mammalian hair growth
11/26/2013CA2731801C Therapeutic formulations for the treatment of cold and flu-like symptoms
11/26/2013CA2610361C Combination of 3-{(2s,4s)-4-[4-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine and a second active agent and use thereof for plasma glucose control
11/26/2013CA2534132C Medicaments for inhalation comprising betamimetics and an anticholinergic
11/26/2013CA2511538C Immunostimulatory combinations
11/26/2013CA2450828C Humanized antibodies derived from dd-3b6/22, specific for the d-dimer fragment of fibrin
11/26/2013CA2425072C Wt1 fusion polypeptides and methods for wt1 immunotherapy
11/26/2013CA2334850C Novel methods and interferon deficient substrates for the propagation of viruses
11/21/2013WO2013173759A2 Macrocyclic nucleoside phosphoramidate derivatives
11/21/2013WO2013173506A2 Method of treating muscular degradation
11/21/2013WO2013173417A2 Glucokinase activator compositions for the treatment of diabetes
11/21/2013WO2013173129A2 Treatment of amd using aav sflt-1
11/21/2013WO2013172927A1 Compositions and methods of vaccination
11/21/2013WO2013172421A1 Ampk protein activator screening method, and ampk protein activator
11/21/2013WO2013170972A1 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and an anticonvulsant
11/21/2013WO2013170971A1 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and a nsar
11/21/2013WO2013170970A1 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and an oxicam
11/21/2013WO2013170969A1 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano'[3,4,b]indol]-4-amine and paracetamol or propacetamol
11/21/2013WO2013170968A1 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro [cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
11/21/2013WO2013170967A1 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
11/21/2013WO2013170966A1 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and a gabapentinoid
11/21/2013WO2013170965A1 Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and antidepressants
11/21/2013WO2013170735A1 Method for treating and/or preventing lung injury
11/21/2013US20130312126 Methods and Compositions for RNAi Mediated Inhibition of Gene Expression in Mammals
11/21/2013US20130310454 Pharmaceutical composition comprising extract of lonicera japonica for prevention and treatment of gastroesophageal reflux disease
11/21/2013US20130310451 Tricyclic lactones for treatment of cancer
11/21/2013US20130310448 Methods and compositions for inhibition of atr and fancd2 activation
11/21/2013US20130310444 Combination Therapy for Cancer
11/21/2013US20130310433 Thiophene-carboxamides useful as inhibitors of protein kinases
11/21/2013US20130310429 ITE for Cancer Intervention and Eradication
11/21/2013US20130310419 Pyrrole derivatives used as modulators of alpha7 nachr
11/21/2013US20130310416 Methods and Compositions for Preventing or Treating Age-Related Diseases
11/21/2013US20130310405 Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway
11/21/2013US20130310396 Thiazolidine derivatives and their therapeutic use
11/21/2013US20130310395 Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1
11/21/2013US20130310392 Pharmaceutical formulation for topical administration comprising b220
11/21/2013US20130310387 Monocyclic Heteroaryl Cycloalkyldiamine Derivatives
11/21/2013US20130310381 Substituted sodium-1h-pyrazole-5-olate
11/21/2013US20130310380 Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer's disease
11/21/2013US20130310364 Compositions and methods for inhibition of the jak pathway
11/21/2013US20130310362 Fused pyrimidines
11/21/2013US20130310361 Compounds and compositions as kinase inhibitors
11/21/2013US20130310357 Azolyl Urea Compounds and Methods of Use Thereof
11/21/2013US20130310354 Combinations comprising antimuscarinic agents and beta-adrenergic agonists
11/21/2013US20130310353 Novel quinuclidine derivatives and medicinal compositions containing the same
11/21/2013US20130310348 Quinoline derivatives and uses thereof
11/21/2013US20130310340 Method of treating muscular degradation
11/21/2013US20130310335 Prolonged release bioadhesive therapeutic systems
11/21/2013US20130310323 Methods of Treating Depression and Other Related Diseases
11/21/2013US20130310321 Diagnostic agent for ischemic heart disease risk group
11/21/2013US20130309330 Compositions comprising a prostaglandin for treating neuropsychiatric conditions
11/21/2013US20130309324 O-nitro compounds and pharmaceutical compositions including same
11/21/2013US20130309323 Compositions and methods for the treatment or prevention of chemoresistant neoplasia
11/21/2013US20130309322 Compositions for improving mental performance
11/21/2013US20130309319 Use of arsenic compounds for treatment of pain and inflammation
11/21/2013US20130309316 Plant derived seed extract rich in essential fatty acids derived from perilla seed: composition of matter, manufacturing process and use
1 ... 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 ... 1151